ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Adolescents and young adults
  • Advocacy
  • Anal cancer
  • Antioxidants
  • AYA
  • Bladder cancer
  • Blood cancers
  • Brain cancer
  • Breast cancer
  • Cancer care delivery
  • Caregiving
  • Chemotherapy
  • Chronic lymphocytic leukemia
  • Colorectal cancer
  • ComboMATCH
  • Communication
  • COVID-19
  • DCIS
  • De-escalation
  • Esophagus cancer
  • Financial hardship
  • Gallbladder cancer
  • Gastroesophageal cancer
  • Geriatric oncology
  • GI cancer
  • Green tea
  • HAI chemotherapy
  • Head and neck cancer
  • Head and neck squamous cell carcinoma
  • Health equity
  • Hepatic arterial infusion chemotherapy.
  • HER2+ breast cancer
  • Hormone therapy
  • Imaging
  • Immune system therapy
  • Immunotherapy
  • Implementation science
  • In memory
  • Kidney cancer
  • Language
  • Late Effects
  • Leiomyosarcoma
  • Leukemia
  • LGBTQ+
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Mantle cell lymphoma
  • Melanoma
  • Men's health
  • Mesothelioma
  • Minimal residual disease
  • MRI
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Myeloma
  • National Clinical Trials Network
  • NCI-MATCH
  • Neuropathy
  • Non-Hodgkin lymphoma
  • Non-small cell lung cancer
  • Nose and sinus cancer
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient advocacy
  • Patient care
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penile cancer
  • Peripheral T-cell lymphoma
  • Personalized medicine
  • Personalized screening
  • Personalized treatment
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Radiation therapy
  • Rare cancer
  • Rare cancers
  • Real-world data
  • Real-world evidence
  • Registry studies
  • Renal cell carcinoma
  • Research results
  • Sarcoma
  • Screening
  • Sexual and gender minorities
  • Side effects
  • Skin cancer
  • Smoldering multiple myeloma
  • Social genomics
  • Soft tissue sarcoma
  • Solid tumors
  • Squamous cell carcinoma
  • Surveillance
  • Survivorship
  • Symptom management
  • Symptom science
  • Targeted therapy
  • Throat cancer
  • Thyroid cancer
  • Trial results
  • Triple-negative breast cancer
  • Tumor test
  • Upper tract urothelial cancer
  • Urothelial cancer
July 2, 2024
July 2, 2024
Categories
  • Editorials

Helping patients navigate their cancer diagnosis, treatment, clinical trial options, and more

Patient navigation services have been shown to improve the patient experience and treatment outcomes
Do you like it?
0 Read more
March 26, 2024
March 26, 2024
Categories
  • Editorials

Improving the publication to practice pipeline: Effective dissemination of research results

Advocates can play an important role in communicating the results of clinical research to their communities
Do you like it?
0 Read more
March 26, 2024
March 26, 2024
Categories
  • New Trials

Now Enrolling: ComboMATCH treatment trial E5 is testing a new option for patients with advanced solid tumors that have a KRAS G12C mutation

This study is assessing the combination of two drugs—sotorasib and panitumumab—in patients with KRAS G12C-mutated solid tumors
Do you like it?
0 Read more
March 26, 2024
March 26, 2024
Categories
  • Ongoing Trials

Ongoing Trial: The EA8192 clinical trial is testing a new treatment approach for patients with upper tract urothelial cancer

This study is for patients with cancer in the lining of the kidney or the tube that connects the kidney to the bladder
Do you like it?
0 Read more
Prev page
123456789101112131415
Next page

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc